HIVACAT has been licensed by the CSIC to develop a vaccine against HIV

The HIVACAT program for the development of this vaccine today announced the obtention of a license to advance in the development of a possible vaccine against HIV —the virus that causes AIDS. The license includes a vaccine candidate called "MVA-B", developed by researcher Mariano Esteban from the Spanish National Research Council (CSIC).

The agreement has been formalized by ESTEVE and the IrsiCaixa Institute for AIDS Research on behalf of HIVACAT. Research, however, will also be conducted at the Hospital Clínic de Barcelona —also part of the HIVACAT consortium.

The obtention of this license coincides with the first anniversary of the presentation in Madrid of very promising results on its efficacy as a preventive vaccine. These results were obtained in a study conducted jointly by the Hospital Clínic of Barcelona and the Gregorio Marañón Hospital of Madrid.